Ask AI
Therapeutic Advancements in LS SCLC

CE / CME

Enhancing Outcomes in Limited-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Pharmacists: 0.25 contact hour (0.025 CEUs)

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: September 18, 2025

Expiration: March 17, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 62-year-old woman (Eastern Cooperative Oncology Group performance status [PS] 1) presents with chest pain and shortness of breath. Chest x-ray shows a right hilar mass. Chest CT demonstrates a 3.4-cm right upper lobe mass with a 3-cm right hilar lymph node. PET/CT is positive only in the right upper lobe and right hilum. Brain MRI is negative. Endobronchial ultrasound–guided biopsy confirms small-cell lung cancer (SCLC) from the right upper lobe mass and a subcarinal node, consistent with limited-stage (LS) SCLC. She receives concurrent chemoradiation therapy (CRT) with cisplatin/etoposide and once-daily thoracic radiotherapy (RT) to 70 Gy, achieving a good partial response without significant toxicity. 

What would you recommend next in this patient’s treatment plan?